Back to Journals » Journal of Hepatocellular Carcinoma » Volume 8

Review

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

       
Total article views   HTML views PDF downloads Totals
14,296 Dovepress* 7,745+ 1,107 8,852
PubMed Central* 6,551 894 7,445
Totals 14,296 2,001 16,297
*Since 15 April 2021
Total mentioned Facebook Delicious Reddit Twitter Others
10 0 0 0 5 5

View citations on PubMed Central and Google Scholar